Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI, FVT

Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting


PHILADELPHIA, March 6, 2024 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting will be held in San Diego from April 5-10.

Details of the poster presentations are as follows:

Title: Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
Presenting Author: Mark Yarchoan, MD
Abstract Number: 1191
Poster Board Number: 25
Session Title: Tumor Immune Response 1
Session Date and Time: Sunday, Apr 7, 2024, 1:30 pm - 5:00 pm PT
Location: San Diego Convention Center, Poster Section 47

Title: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint blockade
Presenting Author: Jian Yan, PhD
Abstract Number: 976
Poster Board Number: 17
Session Title: Circulating Nucleic Acids 1
Session Date and Time: Sunday, April 7, 2024, 1:30 pm - 5:00 pm PT
Location: San Diego Convention Center, Poster Section 40

About Geneos Therapeutics
Geneos Therapeutics, a clinical stage biotherapeutics company, is developing personalized therapeutic cancer vaccines (PTCVs) that may serve an important role in new immunotherapeutic paradigms for cancer. The company's approach, using its proprietary GT-EPICtm platform, is to target neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and uniquely personalized treatments for cancer. Planning is underway for a potentially registrational clinical trial in advanced hepatocellular carcinoma. For more information, please visit www.geneostx.com.

SOURCE Geneos Therapeutics, Inc.


These press releases may also interest you

at 11:49
Philadelphia Jury Returns $10 Million Verdict Against Albert Einstein Medical Center for Deadly Surgery
Philadelphia injury attorney Leonard Hill, founder of Hill & Associates, P.C., represented the estate of Ellen Breen, who died following a minimally invasive surgery that went wrong. Hill's colleague Susan Ayres also assisted in representing the...

at 09:00
Recognize National Women's Health Week by Taking Care of Your Gut Microbiome With Gundry MD Total Restore
National Women's Health Week encourages women to prioritize their well-being through preventive care, healthy habits, and regular check-ups....

at 07:12
ZINZINO AB (PUBL): Zinzino acquires assets in Xeliss - strategic reinforcement in southern Europe and in the microalgae spirulina
Zinzino, the global health and wellness brand from Scandinavia, has acquired, through a business asset acquisition, the rights to the distributor database and associated customer register, inventory, and intellectual property of the Luxembourg-based...

at 05:53
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the...

at 05:43
Second Opinion Expert Announces Strategic Relationship with KangarooHealth
SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that it has entered into a strategic relationship with KangarooHealth, Inc. to improve patient health outcomes, as well as reduce the cost of delivering care by...

11 mai 2024
Fast-Growing Prior Authorization Software Company Announces Addition of Chief Revenue Officer
eBlu Solutions, a leading provider of innovative technology solutions for the specialty healthcare industry, is pleased to announce the addition of Doug Lawrence to the Executive Leadership team in the role of Chief Revenue Officer. "We're not just...

More news about Health...


News published on and distributed by: